Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02673138 · ClinicalTrials.gov registry record · NA

Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion

A NA study of Type 1 Diabetes, sponsored by Yale University.

Completed
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT02673138: Completed NA study of Type 1 Diabetes, sponsored by Yale University.

NCT02673138 is a NA study of Type 1 Diabetes that has completed, run by Yale University. The registered enrollment target is 10 participants, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02673138, a NA study of Type 1 Diabetes, has completed, sponsored by Yale University.

COMPLETED
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

This study will be an open-label, cross-over study as subjects will be studied under both study conditions - suspension of subcutaneous insulin infusion via pump during treatment with insulin alone (control) vs. suspension of subcutaneous insulin via pump during treatment with insulin and canagliflozin.

Primary Outcome

The primary outcome measure for this study will be differences in plasma glucose levels following the interruption of basal subcutaneous infusion of insulin under the two study conditions; i.e., control study during treatment with insulin alone vs. experimental study during treatment with insulin plus canagliflozin or other SGLT2 inhibitor.

Conditions Studied

Interventions

  • DRUG canagliflozin
  • OTHER basal interruption without canagliflozin

Study Locations (1)

Connecticut

  • Yale University School of Medicine - New Haven

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2016-01
Est. Completion 2017-07
Phase NA
Yale University

1,492 total trials

What the finished NCT02673138 record still lists

NCT02673138 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which canagliflozin is the first listed.

NCT02673138 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT02673138 about?

NCT02673138 is a clinical study titled "Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion". This study will be an open-label, cross-over study as subjects will be studied under both study conditions - suspension of subcutaneous insulin infusion via pump during treatment with insulin alone (control) vs. suspension of subcutaneous insulin via pump during treatment with insulin and canagliflo...

What is the current status of trial NCT02673138?

This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2016-01. Estimated completion is 2017-07.

What conditions does trial NCT02673138 study?

This clinical trial studies the following conditions: Type 1 Diabetes.

What interventions are being tested in trial NCT02673138?

The interventions under investigation include: canagliflozin (DRUG), basal interruption without canagliflozin (OTHER).

Who is sponsoring clinical trial NCT02673138?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02673138 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02673138's enrollment target sits among peer trials

10 182nd of 198 higher than 9 of 198 other Type 1 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02673138, the US trial registry maintained by the National Library of Medicine. NCT02673138 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.